LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

Kodu・Aktsiate loetelu・Puma Biotechnology Inc

Puma Biotechnology Inc

Avatud

SektorTervishoid

7.11 2.01

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.91

Max

7.11

Põhinäitajad
By Trading Economics
Sissetulek	-16M -3.8M
Müük	-31M 45M
P/E Sektori keskmine	14.188 49.701
Aktsiakasum	-0.04
Kasumimarginaal	-8.375
Töötajad	179
EBITDA	-28M -1.3M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-28.47% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-37M 347M
Eelmine avamishind	5.1
Eelmine sulgemishind	7.11

Uudiste sentiment

By Acuity

50%

148 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

3.07 / 3.075 Toetus ja vastupanu

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. mai 2026, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21. mai 2026, 16:49 UTC

Tulu

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21. mai 2026, 16:26 UTC

Suurimad hinnamuutused turgudel

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21. mai 2026, 23:51 UTC

Market Talk

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21. mai 2026, 23:37 UTC

Tulu

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21. mai 2026, 23:37 UTC

Tulu

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21. mai 2026, 23:37 UTC

Tulu

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21. mai 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21. mai 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

21. mai 2026, 23:30 UTC

Market Talk

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21. mai 2026, 22:33 UTC

Omandamised, ülevõtmised, äriostud

Conduent to Sell Public Transit Business to Modaxo for $164M

21. mai 2026, 21:53 UTC

Tulu

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21. mai 2026, 21:02 UTC

Tulu

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21. mai 2026, 20:55 UTC

Tulu

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21. mai 2026, 20:30 UTC

Kuumad aktsiad

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21. mai 2026, 20:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. mai 2026, 20:20 UTC

Market Talk

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21. mai 2026, 20:20 UTC

Tulu

Webull 1Q Adj EPS 3c >BULL

21. mai 2026, 20:20 UTC

Tulu

Webull 1Q Rev $159.9M >BULL

21. mai 2026, 20:18 UTC

Market Talk

Mexico's Inflation Seen Easing in Early May -- Market Talk

21. mai 2026, 20:18 UTC

Tulu

Webull 1Q Loss/Shr 4c

21. mai 2026, 19:43 UTC

Market Talk

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21. mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21. mai 2026, 18:58 UTC

Tulu

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21. mai 2026, 18:15 UTC

Market Talk

Gold Higher For Second Consecutive Day -- Market Talk

21. mai 2026, 17:40 UTC

Market Talk

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21. mai 2026, 17:04 UTC

Market Talk

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21. mai 2026, 17:01 UTC

Tulu

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21. mai 2026, 16:20 UTC

Market Talk

Tulu

Stellantis Targets Distant but Constructive -- Market Talk

21. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

-28.47% langus

12 kuu keskmine prognoos

Keskmine 5 USD -28.47%

Kõrge 5 USD

Madal 5 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Puma Biotechnology Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.07 / 3.075Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

148 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.